CA2869280C - Ophthalmic treatments - Google Patents

Ophthalmic treatments Download PDF

Info

Publication number
CA2869280C
CA2869280C CA2869280A CA2869280A CA2869280C CA 2869280 C CA2869280 C CA 2869280C CA 2869280 A CA2869280 A CA 2869280A CA 2869280 A CA2869280 A CA 2869280A CA 2869280 C CA2869280 C CA 2869280C
Authority
CA
Canada
Prior art keywords
eye
composition
aqueous composition
tramadol
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2869280A
Other languages
English (en)
French (fr)
Other versions
CA2869280A1 (en
Inventor
Anant Sharma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Optosolve Research and Development Ltd
Original Assignee
Optosolve Research and Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1105731.2A external-priority patent/GB201105731D0/en
Priority claimed from GBGB1105732.0A external-priority patent/GB201105732D0/en
Application filed by Optosolve Research and Development Ltd filed Critical Optosolve Research and Development Ltd
Publication of CA2869280A1 publication Critical patent/CA2869280A1/en
Application granted granted Critical
Publication of CA2869280C publication Critical patent/CA2869280C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2869280A 2011-04-05 2012-04-05 Ophthalmic treatments Active CA2869280C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1105731.2A GB201105731D0 (en) 2011-04-05 2011-04-05 Topical analgesics
GB1105732.0 2011-04-05
GBGB1105732.0A GB201105732D0 (en) 2011-04-05 2011-04-05 Ophthalmic lubricants
GB1105731.2 2011-04-05
PCT/GB2012/000330 WO2012136969A2 (en) 2011-04-05 2012-04-05 Ophthalmic treatments

Publications (2)

Publication Number Publication Date
CA2869280A1 CA2869280A1 (en) 2012-10-11
CA2869280C true CA2869280C (en) 2020-03-10

Family

ID=46086008

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2869280A Active CA2869280C (en) 2011-04-05 2012-04-05 Ophthalmic treatments

Country Status (12)

Country Link
US (2) US20140088199A1 (https=)
EP (2) EP3799866A1 (https=)
JP (2) JP6148664B2 (https=)
KR (2) KR20140145948A (https=)
CN (2) CN103687594A (https=)
BR (1) BR112013025493A2 (https=)
CA (1) CA2869280C (https=)
ES (1) ES2836808T3 (https=)
HK (1) HK1254720A1 (https=)
MA (1) MA35070B1 (https=)
MX (1) MX346312B (https=)
WO (1) WO2012136969A2 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX346312B (es) * 2011-04-05 2017-03-15 Optosolve Res & Dev Ltd Tratamientos oftalmicos.
GB201217522D0 (en) * 2012-10-01 2012-11-14 Sharma Anant ophthalmic therapy
AU2014252808A1 (en) * 2013-04-09 2015-11-12 Cresset Biomolecular Discovery Ltd The treatment of inflammatory disorders
ES2540151B1 (es) * 2013-10-11 2016-02-29 Farmalider S.A. Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico
RU2549472C1 (ru) * 2013-12-26 2015-04-27 Илья Александрович Марков Фармацевтическая композиция в форме капель для профилактики и лечения аллергических заболеваний глаз
US9913849B2 (en) * 2014-01-10 2018-03-13 Manistee Partners Llc Treatment of migraines
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
KR20170132725A (ko) * 2015-02-24 2017-12-04 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 안구 건조 질환 및 다른 안과 질환을 치료하기 위한 방법 및 조성물
US9877964B2 (en) 2015-02-24 2018-01-30 Ocugen, Inc. Methods and compositions for treating dry eye disease and other eye disorders
HK1248570A1 (zh) 2015-05-29 2018-10-19 西德奈克西斯公司 D2o稳定化的药物制剂
ES2604816B1 (es) * 2015-09-09 2018-01-29 Farmalider, S.A. Composición farmacéutica de tramadol para uso oftálmico
PL3352766T3 (pl) * 2015-09-24 2021-08-02 Matrix Biology Institute Kompozycie z hialuronanem o dużej elastyczności i sposoby ich użycia
EP3355874A4 (en) * 2015-09-30 2019-06-12 George Edward Hoag TOPICAL ANALGETIC FORMULATIONS, MANUFACTURE AND METHOD FOR USE THEREOF
CN105232449B (zh) * 2015-10-30 2019-04-09 上海昊海生物科技股份有限公司 盐酸莫西沙星透明质酸钠缓释纳米凝胶及其制备方法
CN110114119B (zh) * 2016-10-12 2022-05-31 Ps治疗有限公司 人工泪液、隐形眼镜和药物载体组合物及其使用方法
EP3624773A4 (en) 2017-05-19 2021-04-07 Ocugen, Inc. OPHTHALMIC COMPOSITIONS AND METHOD OF USE
RS67824B1 (sr) * 2017-06-08 2026-03-31 Eye Therapies Llc Oftalmološke kompozicije koje sadrže brimonidin i ketotifen za upotrebu u lečenju alergija
WO2019118928A1 (en) * 2017-12-15 2019-06-20 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
WO2019122982A1 (en) 2017-12-21 2019-06-27 Grünenthal GmbH Pharmaceutical combination in a bilayer tablet form comprising ketorolac tromethamine and tramadol hydrochloride, and its use in pain treatment
JP7370316B2 (ja) * 2018-03-13 2023-10-27 参天製薬株式会社 点眼型洗眼薬用組成物
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
WO2021018750A1 (en) 2019-07-26 2021-02-04 Proqr Therapeutics Ii B.V. Ophthalmic compositions comprising viscosifying polymers and nucleic acids
US11504269B2 (en) 2019-11-19 2022-11-22 Jennifer L. Fabian Therapeutic bra
US20230077811A1 (en) * 2020-02-11 2023-03-16 Tufts Medical Center, Inc. Activation of neuropeptide receptors on plasmacytoid dendritic cells to treat or prevent ocular diseases associated with neovascularization and inflammation
US20230218726A1 (en) * 2020-04-23 2023-07-13 Okogen, Inc. Treatment of viral conjunctivitis
CN112007028A (zh) * 2020-09-03 2020-12-01 北京博纳致恒科技有限责任公司 一种复合睫状肌松弛剂的人工泪液及用途
JP2024509372A (ja) * 2021-02-26 2024-03-01 ヴァイルマ インコーポレイテッド ガバペンチノイドの局所投与のための方法及び製剤
WO2023285878A1 (en) * 2021-07-13 2023-01-19 Aviation-Ophthalmology Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
WO2024010040A1 (ja) * 2022-07-06 2024-01-11 ロート製薬株式会社 眼科組成物
WO2024010045A1 (ja) * 2022-07-06 2024-01-11 学校法人金沢医科大学 疼痛抑制剤
JPWO2024010044A1 (https=) * 2022-07-06 2024-01-11
TW202408472A (zh) * 2022-07-06 2024-03-01 日商樂敦製藥股份有限公司 眼科組成物
WO2025146828A1 (ja) * 2024-01-05 2025-07-10 ロート製薬株式会社 眼科組成物
WO2025159099A1 (ja) * 2024-01-24 2025-07-31 国立大学法人北海道大学 医薬組成物、眼瞼けいれん処置薬、知覚過敏またはジストニア処置薬、および症状モデルマウス

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6384043B1 (en) 1993-02-01 2002-05-07 Gholam A. Peyman Methods of alleviating pain sensations of the denuded eye with opioid analgesics
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
ES2174337T3 (es) * 1996-12-16 2002-11-01 Alcon Lab Inc Uso topico de los agonistas opioides kappa para el tratamiento del dolor ocular.
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
JP2004143157A (ja) * 2002-10-01 2004-05-20 Taisho Pharmaceut Co Ltd 点眼剤
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
WO2005117830A1 (en) * 2004-06-04 2005-12-15 Camurus Ab Liquid depot formulations
EP1611877A1 (en) * 2004-06-28 2006-01-04 Universidade de Coimbra Method for preparing sustained-release therapeutic ophthalmic articles using compressed fluids for impregnation of drugs
WO2007057508A2 (en) * 2005-11-18 2007-05-24 Orion Corporation Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol
AU2007208054A1 (en) * 2006-01-25 2007-08-02 Aciex Therapeutics, Inc. Formulations and methods for treating dry eye
CN101754748A (zh) 2007-05-24 2010-06-23 阿西克斯医疗公司 治疗干眼症的制剂和方法
EP2311446A1 (en) * 2009-10-16 2011-04-20 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising Tramadol and Celecoxib in the treatment of pain
MX346312B (es) * 2011-04-05 2017-03-15 Optosolve Res & Dev Ltd Tratamientos oftalmicos.

Also Published As

Publication number Publication date
JP2014513073A (ja) 2014-05-29
HK1254720A1 (zh) 2019-07-26
MA35070B1 (fr) 2014-04-03
US9913813B2 (en) 2018-03-13
US20160199320A1 (en) 2016-07-14
CN107982211A (zh) 2018-05-04
KR20190004815A (ko) 2019-01-14
EP2694048A2 (en) 2014-02-12
KR102165246B1 (ko) 2020-10-13
WO2012136969A2 (en) 2012-10-11
JP2017141243A (ja) 2017-08-17
ES2836808T3 (es) 2021-06-28
MX346312B (es) 2017-03-15
US20140088199A1 (en) 2014-03-27
JP6148664B2 (ja) 2017-06-14
CA2869280A1 (en) 2012-10-11
WO2012136969A3 (en) 2013-01-03
BR112013025493A2 (pt) 2017-03-01
EP2694048B1 (en) 2020-10-07
EP3799866A1 (en) 2021-04-07
CN103687594A (zh) 2014-03-26
MX2013011314A (es) 2014-03-27
JP6419876B2 (ja) 2018-11-07
KR20140145948A (ko) 2014-12-24

Similar Documents

Publication Publication Date Title
US9913813B2 (en) Opthalmic treatments
CA2810537C (en) Compositions for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye
ES2812532T3 (es) Compuestos, formulaciones y procedimientos para tratar o prevenir la rosácea
ES2759781T3 (es) Composiciones y tratamiento para enfermedades y trastornos oculares
JP2014513073A5 (https=)
US20110294897A1 (en) Treating Xerophthalmia With Compounds Increasing Meibomian Gland Secretion
Bielory et al. Emerging therapeutics for ocular surface disease
WO2017042404A1 (es) Composición farmacéutica de tramadol para uso oftálmico
So et al. Emerging trends in long-acting sustained drug delivery for glaucoma management
KR20200089703A (ko) 안구주위 분비선 또는 안구 표면에서의 이상 염증을 치료하기 위한 조성물 및 사용 방법
JP2004002358A (ja) 眼科用組成物
EP2979689A1 (en) Composition for an eye drop and delivery system therefor
Rathore et al. An overview and advancement in ocular drug delivery systems
CN115634226B (zh) 一种采用长春西汀治疗近视的方法
Williams et al. The birth of ocular pharmacology in the 20th century
Hughes et al. Ocular surface anatomy and physiology: impact on product development
KR20230098630A (ko) 노안의 예방, 제어 및 근절에 효과적인 저농도 투여량의 상승적 안과 조성물
CN103202833A (zh) 一种奥洛他定或其盐的药用组合物及其制备方法
Singh et al. Adverse effects of antiglaucoma medications: pathophysiology and novel drug delivery strategies for mitigation
RU2772357C2 (ru) Состав для эффективной доставки липидов в слезную пленку человека с использованием чувствительной к соли эмульсионной системы
US20230064711A1 (en) Compositions, kits and methods for enhancing therapeutic compliance

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170223

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240923

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240923

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240923

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250922

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250922

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251128